PCI Biotech Holding ASA publishes the Annual Report 2021
28 Abril 2022 - 3:58AM
PCI Biotech Holding ASA publishes the Annual Report 2021
Oslo, Norway, April 28, 2022The Board of
Directors of PCI Biotech Holding ASA has approved the Annual Report
2021 and the report is attached, in addition to the report
according to the European Single Electronic Format (ESEF). The
Annual Report 2021 is also available on the company’s website
www.pcibiotech.com.
For further information, please
contact: PCI Biotech
Holding ASA, Ullernchausséen 64, N-0379
Oslo Per Walday,
CEO, pw@pcibiotech.no, Mobile: +47 917
93 429 Ronny
Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 940 05 757
About PCI
Biotech PCI
Biotech is a biopharmaceutical clinical stage development company
focusing on development and commercialisation of novel therapies
for the treatment of cancer through its innovative photochemical
internalisation (PCI) technology platform. PCI induces triggered
endosomal release that is used to unlock the true potential of
therapeutic modalities.
The company’s lead programme
fimaVacc aims to enhance
immunotherapy in cancer, by triggered endosomal release of antigens
or nucleic acids encoding antigens, or immunostimulatory factors.
Enhancement of relevant immune responses with protein- and
peptide-based vaccines were successfully demonstrated in humans
through an extensive Phase I study in healthy volunteers and a
Phase II study is in planning with the aim to demonstrate
enhancement of immunotherapy for treatment of solid tumours. In the
fimaNAc programme endosomal
release is utilised to provide intracellular delivery of nucleic
acids, such as mRNA and RNAi therapeutics, thereby addressing one
of the major bottlenecks facing this emerging and promising
field.
For further information, please visit:
www.pcibiotech.com Contact
information: PCI Biotech Holding ASA, Ullernchausséen 64,
N-0379
Oslo
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
- 2021 Annual report PCI Biotech Holding ASA
- pcibiotechholdingasa-2021-12-31-en
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
